Evidence map›Paper›PMID 38632527›Full record

ArticleBiological procedures online2024

Development of an Interpretable Deep Learning Model for Pathological Tumor Response Assessment After Neoadjuvant Therapy.

Yichen Wang, Wenhua Zhang, Lijun Chen, Jun Xie, Xuebin Zheng, Yan Jin, Qiang Zheng, Qianqian Xue, Bin Li, Chuan He and 2 more

Open access · goldAbstract read
In one paragraph

Article in Biological procedures online, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Yichen Wang *Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China, 200032.
Wenhua Zhang *Shanghai Aitrox Technology Corporation Limited, Shanghai, China.
Lijun ChenDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China, 200032.
Jun XieShanghai Aitrox Technology Corporation Limited, Shanghai, China.
Xuebin ZhengShanghai Aitrox Technology Corporation Limited, Shanghai, China.
Yan JinDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China, 200032.
Qiang ZhengDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China, 200032.
Qianqian XueDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China, 200032.
Bin LiDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China, 200032.
Chuan HeShanghai Aitrox Technology Corporation Limited, Shanghai, China.
Haiquan ChenDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China, 200032.
Yuan LiDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China, 200032. lumoxuan2009@163.com.
Shanghai Medical College of Fudan University · CNFudan University Shanghai Cancer Center · CNShanghai University · CN

Funding

National key research and development program of China 2021YFF1201001National Nature Science Foundation of China 81972171
6 · The paper itself

Abstract

backgroundNeoadjuvant therapy followed by surgery has become the standard of care for locally advanced esophageal squamous cell carcinoma (ESCC) and accurate pathological response assessment is critical to assess the therapeutic efficacy. However, it can be laborious and inconsistency between different observers may occur. Hence, we aim to develop an interpretable deep-learning model for efficient pathological response assessment following neoadjuvant therapy in ESCC.

methodsThis retrospective study analyzed 337 ESCC resection specimens from 2020-2021 at the Pudong-Branch (Cohort 1) and 114 from 2021-2022 at the Puxi-Branch (External Cohort 2) of Fudan University Shanghai Cancer Center. Whole slide images (WSIs) from these two cohorts were generated using different scanning machines to test the ability of the model in handling color variations. Four pathologists independently assessed the pathological response. The senior pathologists annotated tumor beds and residual tumor percentages on WSIs to determine consensus labels. Furthermore, 1850 image patches were randomly extracted from Cohort 1 WSIs and binarily classified for tumor viability. A deep-learning model employing knowledge distillation was developed to automatically classify positive patches for each WSI and estimate the viable residual tumor percentages. Spatial heatmaps were output for model explanations and visualizations.

resultsThe approach achieved high concordance with pathologist consensus, with an R^2 of 0.8437, a RAcc_0.1 of 0.7586, a RAcc_0.3 of 0.9885, which were comparable to two senior pathologists (R^2 of 0.9202/0.9619, RAcc_0.1 of 8506/0.9425, RAcc_0.3 of 1.000/1.000) and surpassing two junior pathologists (R^2 of 0.5592/0.5474, RAcc_0.1 of 0.5287/0.5287, RAcc_0.3 of 0.9080/0.9310). Visualizations enabled the localization of residual viable tumor to augment microscopic assessment.

conclusionThis work illustrates deep learning's potential for assisting pathological response assessment. Spatial heatmaps and patch examples provide intuitive explanations of model predictions, engendering clinical trust and adoption (Code and data will be available at https://github.com/WinnieLaugh/ESCC_Percentage once the paper has been conditionally accepted). Integrating interpretable computational pathology could help enhance the efficiency and consistency of tumor response assessment and empower precise oncology treatment decisions.

Indexed as

Esophageal Squamous CarcinomaImmunochemotherapyKnowledge DistillationPathological Tumor ResponseSemi-supervised Learning

Identifiers

PMID38632527
PMCPMC11022344
OpenAlexW4394890580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.